Inactive Instrument

Neos Therapeutics, Inc.

NEOS

US64052L1061

Neos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020

November 09, 2020 at 07:32 am EST

Neos Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 2.916 million compared to USD 433,000 a year ago. Net loss was USD 4.911 million compared to USD 2.051 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.04 a year ago. For the nine months, operating loss was USD 11.679 million compared to USD 8.700 million a year ago. Net loss was USD 18.369 million compared to USD 13.414 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.27 a year ago.

Latest news about Neos Therapeutics, Inc.

Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers	22-01-31	CI
Aytu BioScience : Completes Merger With Neos Therapeutics	21-03-22	MT
Neos Therapeutics, Inc. Announces Board Changes	21-03-22	CI
Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer	21-03-22	CI
Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer	21-03-22	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index	21-03-22	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index	21-03-19	CI
Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..	21-03-18	CI
Transcript : Neos Therapeutics, Inc. - Shareholder/Analyst Call	21-03-18
Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis	21-03-12	MT
Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March	21-02-10	MT
Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.	21-02-07	CI
DJ Industrial : Wall Street Slips Pre-Bell as Stimulus Impasse Drags, Jobless Claims Surge	20-12-10	MT
Neos Therapeutics : Aytu BioScience and Neos Therapeutics Enter Definitive Merger Deal	20-12-10	MT
Transcript : Aytu BioScience, Inc., Neos Therapeutics, Inc. - M&A Call	20-12-10
Aytu BioScience, Inc. entered into definitive merger agreement to acquire Neos Therapeutics, Inc. for $37.8 million.	20-12-09	CI
Neos Therapeutics, Inc. announced that it expects to receive $5 million in funding from Aytu BioScience, Inc.	20-12-09	CI
Transcript : Neos Therapeutics, Inc., Q3 2020 Earnings Call, Nov 09, 2020	20-11-09
Neos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Transcript : Neos Therapeutics, Inc., Q2 2020 Earnings Call, Aug 10, 2020	20-08-10
Neos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from Russell Microcap Growth Index	20-06-26	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from Russell Microcap Index	20-06-26	CI
Neos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Transcript : Neos Therapeutics, Inc., Q1 2020 Earnings Call, May 11, 2020	20-05-11

Chart Neos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals